Blood-based protein biomarkers for diagnosis and classification of neurodegenerative diseases: current progress and clinical potential

Mol Diagn Ther. 2011 Apr 1;15(2):83-102. doi: 10.1007/BF03256398.

Abstract

Biomarker research is a rapidly advancing field in medicine. Recent advances in genomic, genetic, epigenetic, neuroscientific, proteomic, and metabolomic knowledge and technologies have opened the way to thriving research. In the most general sense, a biomarker refers to any useful characteristic that can be measured and used as an indicator of a normal biologic process, a pathogenic process, or a pharmacologic response to a therapeutic agent. Despite the extensive resources concentrated on this area, there are very few biomarkers currently available that qualify and are satisfactorily validated for mental disorders, and there is still a major lack of biomarkers for typifying neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease. This article provides an overview of this field of research and focuses on recent advances in biomarker research in Alzheimer's disease and Parkinson's disease.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Alzheimer Disease / blood
  • Alzheimer Disease / cerebrospinal fluid
  • Alzheimer Disease / diagnosis
  • Animals
  • Biomarkers / blood*
  • Biomarkers / cerebrospinal fluid
  • Humans
  • Neurodegenerative Diseases / blood*
  • Neurodegenerative Diseases / cerebrospinal fluid
  • Neurodegenerative Diseases / diagnosis*
  • Parkinson Disease / blood
  • Parkinson Disease / cerebrospinal fluid
  • Parkinson Disease / diagnosis

Substances

  • Biomarkers